Soluble CD40 Ligand, Plasminogen Activator Inhibitor-1 and Thrombin-Activatable Fibrinolysis Inhibitor-1-Antigen in Normotensive Type 2 Diabetic Subjects without Diabetic Complications

By  

Medical Principles and Practice, Vol. 18, Iss. 4, 2009-06 ,pp. : 266-271

Karger

Access to resources Recommend Favorite

Molecular Advances in Plasminogen Activator Inhibitor 1 Interaction with Thrombin and Tissue-Type Plasminogen Activator

By Stoop A.   van Meijer M.   Horrevoets A.J.G.   Pannekoek H.  

Trends in Cardiovascular Medicine, Vol. 7, Iss. 2, 1997-02 ,pp. : 47-51

Elsevier

Access to resources Recommend Favorite

Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model

By Yamada K.   Tsuji H.   Kimura S.   Kato H.   Yano S.   Ukimura N.   Yamada Y.   Nakagawa K.   Nakagawa M.  

Thrombosis Research, Vol. 109, Iss. 1, 2003-01 ,pp. : 55-64

Elsevier

Access to resources Recommend Favorite

Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients

By  

Medical Principles and Practice, Vol. 20, Iss. 4, 2011-05 ,pp. : 332-335

Karger

Access to resources Recommend Favorite

Tissue-type plasminogen activator gene targets thrombolysis in atriums

By Gong Yongsheng   Wang Fajiu   Li Xia   Gao Zhixin   Zhang Kailun   Fan Chen   Liu Xingen  

Journal of Thrombosis and Thrombolysis, Vol. 30, Iss. 4, 2010-11 ,pp. : 507-514

Springer Publishing Company

Access to resources Recommend Favorite